Harvard Bioscience (HBIO) to Release Quarterly Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIOGet Free Report) will be posting its quarterly earnings results on Tuesday, April 23rd.

Harvard Bioscience (NASDAQ:HBIOGet Free Report) last posted its earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Harvard Bioscience had a negative net margin of 3.04% and a positive return on equity of 2.75%. The business had revenue of $28.15 million during the quarter, compared to the consensus estimate of $27.80 million.

Harvard Bioscience Stock Performance

Shares of NASDAQ:HBIO opened at $3.70 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.85 and a quick ratio of 0.92. The business’s fifty day moving average price is $4.32 and its two-hundred day moving average price is $4.50. Harvard Bioscience has a fifty-two week low of $3.69 and a fifty-two week high of $6.29. The stock has a market capitalization of $160.58 million, a price-to-earnings ratio of -46.24 and a beta of 1.42.

Institutional Investors Weigh In On Harvard Bioscience

Hedge funds have recently made changes to their positions in the company. B. Riley Asset Management LLC grew its stake in Harvard Bioscience by 6.9% during the first quarter. B. Riley Asset Management LLC now owns 3,408,796 shares of the medical instruments supplier’s stock worth $14,317,000 after buying an additional 221,500 shares during the last quarter. Punch & Associates Investment Management Inc. boosted its stake in Harvard Bioscience by 6.6% in the first quarter. Punch & Associates Investment Management Inc. now owns 2,947,329 shares of the medical instruments supplier’s stock worth $12,379,000 after purchasing an additional 183,290 shares in the last quarter. BlackRock Inc. boosted its stake in Harvard Bioscience by 190.0% in the second quarter. BlackRock Inc. now owns 2,623,751 shares of the medical instruments supplier’s stock worth $14,404,000 after purchasing an additional 1,719,006 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Harvard Bioscience by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 2,102,571 shares of the medical instruments supplier’s stock worth $11,249,000 after purchasing an additional 38,169 shares during the last quarter. Finally, Granahan Investment Management LLC increased its stake in shares of Harvard Bioscience by 6.2% in the fourth quarter. Granahan Investment Management LLC now owns 1,843,484 shares of the medical instruments supplier’s stock valued at $9,863,000 after buying an additional 107,912 shares in the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

About Harvard Bioscience

(Get Free Report)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

Read More

Earnings History for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.